Ondine Appoints Dr. Angelo Mariotti to Clinical Advisory Board

    VANCOUVER, Oct. 29 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM:
OBP), a medical technology company developing photodisinfection, today
announced that it has appointed Dr. Angelo Mariotti to its Clinical Advisory
Board (CAB).
    Dr. Mariotti is a Professor and Chair, Section of Periodontology, College
of Dentistry at the Ohio State University and Adjunct Professor, Periodontics
and Preventive Dentistry, at the University of Pittsburgh. He has held
instructor and assistant professor positions at West Virginia University,
Virginia Commonwealth University and University of Florida. He is on the
editorial board and advisory board of the Journal of Periodontology, and is
the editor of the Pharmacology and Therapeutics for Dentistry, 6th edition,
2008 and sits on the expert panel on Bisphosphonates, Council on Scientific
Affairs of the ADA. In addition to an extensive publication list of papers,
abstracts and book chapters, Dr. Mariotti lectures at both national and
international conferences and has chaired key sessions at the IADR, AAP and
    "We are very pleased that Dr. Mariotti has accepted our invitation to sit
on Ondine's Clinical Advisory Board," said Carolyn Cross, President & CEO,
Ondine Biopharma, "Dr. Marriotti's background in both pharmacology and
therapeutics in dentistry complement the capabilities and reputations of our
other Clinical Advisory Board members. Dr. Marriotti will be an important
resource to Ondine as the Company explores ways to expand the brand through
the development of further applications and markets for Periowave(TM)."
    Additional information relating to the members of the Clinical Advisory
Board can be found on our website www.ondinebiopharma.com.

    About Periowave(TM) and Photodisinfection

    Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
photosensitive compounds to specifically target and destroy microbial
pathogens and reduce the symptoms of disease. The compounds are topically
applied and lasers of appropriate wavelength and intensity are used to
disinfect the treatment site. The Company's Periowave(TM) photodisinfection
system is currently approved in Canada for nasal eradication of pathogenic
bacteria such as MRSA and the oral treatment of periodontitis, gingivitis,
peri-implantitis, peri-mucositis, endodontics, and in the European Union for
nasal eradication of MRSA, adult periodontitis, endodontics and
peri-implantitis. The photodynamic disinfection technologies were developed by
Professor Michael Wilson and colleagues at the Eastman Dental Institute,
University College London, and licensed to Ondine by UCL Business PLC,
University College London.

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is headquartered in Vancouver, British
Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and
an international office in St. Michael, Barbados. For additional information,
please visit the Company's website at: www.ondinebiopharma.com

    The TSX Exchange has not reviewed and does not accept responsibility for
    the adequacy or accuracy of this release.

For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com; Irma
Gomez-Dib, Media & Investors Relations, FD International, (212) 850-5761,
Irma.gomez.dib@fd.com; Nominated Adviser, Neil Johnson/Ryan Gaffney, Canaccord
Adams Ltd, +44(0)20 7050 6500

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890